Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance - Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma PLC (NASDAQ:RPRX) reported Q1 2023 total income and other revenues increase of 22% Y/Y to $684 million, missing the consensus of $852.9 million.
Adjusted EBITDA increased 88% Y/Y to $1.04 billion. Adjusted cash receipts were up 87% Y/Y to $1.13 billion, led by Pfizer Inc's (NYSE:PFE) Zavzpret milestone and improved portfolio performance.
Adjusted EPS of $1.60 beat the analysts' expectation of $1.27.
Net cash provided by operating activities rose 125% Y/Y to $1.03 billion, led by payment receipt related to the FDA approval of Zavzpret, strong portfolio performance and payment linked to commercialization of Airsupra in the U.S. by AstraZeneca PLC (NYSE:AZN).
As of March 31, 2023, cash, cash equivalents and marketable securities stood at $2.0 billion.
In March, the company's Board of Directors approved a share buyback program of up to $1.0 billion through June 2027.
2023 Outlook Reaffirmed: RPRX expects adjusted cash reciepts of $2.85 billion to $2.95 billion, reflecting payment of $475 million related to FDA approval of Zavzpret.
"We announced transactions of up to $1.6 billion to acquire royalties on three innovative therapies, which further diversified our portfolio. In addition, we announced a multi-year share repurchase program of up to $1.0 billion. This reflects our confidence in Royalty Pharma's attractive outlook for compounding growth and our disciplined capital allocation strategy to create shareholder value," stated Pablo Legorreta, founder and CEO.
Price Action: RPRX shares are trading lower by 3.05% at $34.44 on the last check Tuesday.

RPRXRoyalty Pharma PLC

$54.390.22%

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.